retatrutide type 2 diabetes phase 2 results 2024 2025 Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized 2a trial retatrutide phase 2 trial type

One finding that particularly stands out: liver fat reduction

If you observe any side effects, consult your healthcare provider immediately

Users frequently describe waking up feeling more refreshed despite similar total sleep duration, suggesting improvements in sleep quality beyond simple duration metrics

RELATED: Retatrutide vs

No sign that this medication is doing anything at all

Long-Term Weight Loss and Metabolic Health Benefits Over multiple months of continuous dosing, participants in clinical trials exhibited improved insulin sensitivity, reduced blood sugar, lower blood pressure, and enhanced metabolic health markers